Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Seres Therapeutics (MCRB) Total Liabilities (2016 - 2025)

Seres Therapeutics (MCRB) has disclosed Total Liabilities for 11 consecutive years, with $94.0 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities fell 25.43% to $94.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $94.0 million through Dec 2025, down 25.43% year-over-year, with the annual reading at $94.0 million for FY2025, 25.43% down from the prior year.
  • Total Liabilities hit $94.0 million in Q4 2025 for Seres Therapeutics, down from $99.8 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $408.8 million in Q2 2024 to a low of $94.0 million in Q4 2025.
  • Historically, Total Liabilities has averaged $242.1 million across 5 years, with a median of $231.1 million in 2021.
  • Biggest five-year swings in Total Liabilities: skyrocketed 56.71% in 2023 and later plummeted 72.88% in 2025.
  • Year by year, Total Liabilities stood at $223.4 million in 2021, then surged by 51.33% to $338.0 million in 2022, then grew by 19.37% to $403.5 million in 2023, then plummeted by 68.76% to $126.0 million in 2024, then dropped by 25.43% to $94.0 million in 2025.
  • Business Quant data shows Total Liabilities for MCRB at $94.0 million in Q4 2025, $99.8 million in Q3 2025, and $110.8 million in Q2 2025.